Cargando…
Update on the role of candesartan in the optimal management of hypertension and cardiovascular risk reduction
Hypertension is the most prevalent cardiovascular disease of adults and is a major risk factor for cardiovascular (CV) and cerebrovascular morbidity and mortality worldwide. Treatment of hypertension leads to reduction of CV morbidity and mortality through blood pressure reduction. The role of renin...
Autores principales: | Okpechi, Ikechi G, Rayner, Brian L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3172071/ https://www.ncbi.nlm.nih.gov/pubmed/21949620 |
Ejemplares similares
-
Telehealth and Management Support for Hypertension in CKD: Time to Raise the Bar
por: Okpechi, Ikechi G., et al.
Publicado: (2023) -
Cost Effectiveness Analysis of Candesartan Therapy in Comparison to Candesartan-Amlodipine Therapy on Hypertensive Outpatients
por: Baroroh, Faridah, et al.
Publicado: (2019) -
Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension
por: Kjeldsen, S E, et al.
Publicado: (2010) -
Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T)
por: Bönner, Gerd, et al.
Publicado: (2011) -
Health-care costs of losartan and candesartan in the primary treatment of hypertension
por: Henriksson, M, et al.
Publicado: (2011)